Washington University School of Medicine Digital Commons@Becker

Open Access Publications

2021

Recessive COL4A2 mutation leads to intellectual disability, epilepsy, and spastic cerebral palsy

Somayeh Bakhtiari

Abbas Tafakhori

Sheng Chih Jin

Brandon S. Guida

Elham Alehabib

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Authors

Somayeh Bakhtiari, Abbas Tafakhori, Sheng Chih Jin, Brandon S. Guida, Elham Alehabib, Saghar Firouzabadi, Kaya Bilguvar, Michael C. Fahey, Hossein Darvish, and Michael C. Kruer

Recessive COL4A2 Mutation Leads to Intellectual Disability, Epilepsy, and Spastic **Cerebral Palsy**

Somayeh Bakhtiari, PhD, Abbas Tafakhori, MD, Sheng Chih Jin, PhD, Brandon S. Guida, PhD, Elham Alehabib, PhD, Saghar Firouzbadi, PhD, Kaya Bilguvar, MD, Michael C. Fahey, PhD, Hossein Darvish, PhD,* and Michael C. Kruer, MD*

Neurol Genet 2021;7:e583. doi:10.1212/NXG.000000000000583

Dominant negative or haploinsufficient mutations in the collagen genes COL4A1 and COL4A2 are characterized by arterial basement membrane thickening resulting in a multisystem microangiopathy targeting the CNS but also potentially affecting the ocular, renal, cardiac, and muscular systems. Within the brain, such changes predispose affected individuals to recurrent ischemic and/or hemorrhagic strokes beginning during early fetal development but extending into the postnatal period and even into adulthood.¹ Mutations affecting glycine residues of the Gly-Xaa-Yaw (typically representing glycine-proline-4-trans-hydroxyproline in vertebrates) repeat domains that typify collagens usually manifest in an autosomal dominant (AD) fashion. However, recent work suggests that tissue-specific mutation effects may also occur, with mutations leading to gain of function effects in some tissues and loss of function effects in others.² Stroke-related complications may be insidious and clinically silent. Neuroimaging phenotypes of COL4A-associated disease include chronic white matter disease, porencephaly/hydranencephaly, encephalomalacia, cerebral calcifications, schizencephaly and hydrocephalus and corresponding clinical diagnoses of cerebral palsy, intellectual disability, cortical visual impairment, and epilepsy.³

Type IV collagen α chains form heterotrimers with β chains in a 2:1 ratio, and incompletely penetrant AD inheritance is typical. Although autosomal recessive mutations of COL4A1 have been described,⁴ prior reports of COL4A2-associated disease have all featured AD inheritance. We describe 2 children from a consanguineous Iranian family with intellectual disability, spastic cerebral palsy, and epilepsy who each harbored the same homozygous mutation in COL4A2.

Pregnancies for both children were uncomplicated, and both were born at term by vaginal delivery. The couple's 8 year-old son was bedridden and exhibited cortical visual impairment. He did not fix or track stimuli. He had never been able to sit unassisted or control his head. He did not speak or demonstrate communicative intent. He had focal epilepsy that began at age 6 months, partially controlled with carbamazepine. Motor examination revealed spastic quadriplegia with ophthalmoplegia, nystagmus, and skew deviation. Brain MRI revealed bilateral colpocephaly and irregular ventricular contours. His sister was 20 years old at the time of evaluation. Milestone attainment had been globally delayed. She also had focal epilepsy with onset at 18 months. Seizures were controlled with phenobarbital and carbamazepine. She began walking independently at age 3 years. At the time of evaluation, she did not speak, and her

Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.

gnomAD: gnomad.broadinstitute.org/

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Correspondence Dr. Kruer mkruer@phoenixchildrens.com

^{*}Both authors jointly supervised this work.

From the Pediatric Movement Disorders Program (S.B., B.S.G., M.C.K.), Barrow Neurological Institute, Phoenix Children's Hospital, AZ; Departments of Child Health (S.B., B.S.G., M.C.K.), Neurology, Genetics, and Cellular & Molecular Medicine, University of Arizona College of Medicine Phoenix, Phoenix, AZ; Iranian Center of Neurological Research (A.T., H.D.), Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; Department of Genetics (S.C.J.), Washington University School of Medicine, St. Louis, MO; Student Research Committee (E.A.), School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Genetics Research Center (S.F.), University of Social Welfare and Rehabilitation Sciences, Tehran, Iran; Department of Genetics (K.B.), Yale University, New Haven, CT; and Department of Paediatrics (M.C.F.), Monash University, Melbourne, Victoria, Australia.

The Article Processing Charge was funded by NIH 1R01NS106298.

GME Variome server: igm.ucsd.edu/gme/

Corresponding author Michael Kruer takes responsibility for the accuracy of the data presented, the conduct of the research, providing access to the original data, and the right to publish.

Figure Clinical, Neuroimaging, and Genetic Findings in the Index Family



(A) Pedigree demonstrating variant segregation. (B) Brain MRI findings from the affected sister demonstrate colpocephaly, irregular ventricular contours, encephalomalacia affecting the left greater than right caudate, putamen, globus pallidus, and thalamus, periventricular white matter injury, and thin corpus callosum. (C) Protein schematic with mapping of autosomal dominant mutations previously described and autosomal recessive variant described in this study (green = collagen triple helices; pink = procollagen C-terminal repeat domain; black variants indicate ischemic disease; red variants indicate hemorrhagic disease; purple variants indicate porencephaly; homozygous variant from this study bolded and underlined).

examination was significant for asymmetric spastic-dystonic quadriparesis with right-sided predominance. Her brain MRI showed irregular lateral ventricle contour with coalescent porencephaly and generalized cortical atrophy (figure, A). Neither patient was known to have ocular, kidney, skeletal, or cardiac muscle disease.

Both affected children and their parents provided informed consent for study participation in accordance with local ethics oversight and underwent whole-exome sequencing with filtering and variant prioritization as described previously.⁵ This revealed a homozygous c.3472G>C (p.G1158R) variant in COL4A2 (NM 001846) segregating with disease status in the family (both parents are neurologically healthy, although neuroimaging was not able to be performed) (figure, B). This variant is novel (not found in gnomAD or the Greater Middle Eastern Variome server) and predicted to be deleterious (MetaSVM, CADD, SIFT, and PolyPhen), putatively by disrupting a glycine residue within a highly conserved Gly-Xaa-Yaw collagen triple helix repeat domain. Such glycine residues are known to be critical determinants of collagen stability and we anticipate that the substitution of an arginine residue to have a destabilizing effect.⁶

In comparison to previously described incompletely penetrant dominantly inherited mutations in *COL4A2*, this homozygous (p.G1158R) variant appears to exhibit autosomal recessive inheritance, although our observations will benefit from subsequent confirmation. Our results indicate that both dominant and recessive forms of *COL4A2* disease exist. This finding has potentially important implications for the interpretation of clinical genetic testing in cases of porencephaly, hydrocephalus or idiopathic antenatal or perinatal ischemic/hemorrhagic stroke and for associated clinical phenotypes including epilepsy, intellectual disability, and cerebral palsy.⁷

Data Availability

Full data are available to qualified investigators on reasonable request to the corresponding author.

Acknowledgment

The authors thank the patients and their family members for their support of this work.

Study Funding

NIH; 1R01 NS106298.

Disclosure

MCK serves as a consultant for PTC Therapeutics and the United States National Health Services Administration and has performed grant review for the United States Department of Defense. The remaining authors report no disclosures related to the conduct of this manuscript. Bioinformatic and statistical analysis performed by SB and SCJ. Go to Neurology.org/NG for full disclosures.

Publication History

Received by *Neurology: Genetics* September 21, 2020. Accepted in final form February 15, 2021.

Appendix Authors

Name	Location	Contribution
Somayeh Bakhtiari, PhD	Phoenix Children's Hospital	Designed and conducted bioinformatic analysis and revised the manuscript for important intellectual content
Abbas Tafakhori, MD	Tehran University of Medical Sciences	Enrolled participants; performed clinical phenotyping; and revised the manuscript for important intellectual content
Sheng Chih Jin, PhD	Washington University, St. Louis	Designed bioinformatic analysis and revised the manuscript for important intellectual content
Brandon S. Guida, PhD	Phoenix Children's Hospital	Designed and conceptualized the study and revised the manuscript for important intellectual content
Elham Alehabib, PhD	Shahid Beheshti University of Medical Sciences	Enrolled participants; performed clinical phenotyping; and revised the manuscript for important intellectual content
Saghar Firouzabadi, PhD	University of Social Welfare and Rehabilitation Sciences, Tehran	Enrolled participants; performed clinical phenotyping; and revised the manuscript for important intellectual content

Appendix (continued)		
Name	Location	Contribution
Kaya Bilguvar, MD	Yale University	Designed and conceptualized the study and revised the manuscript for important intellectual content
Michael C. Fahey, PhD	Monash University	Designed and conceptualized the study and revised the manuscript for important intellectual content
Hossein Darvish, PhD	Tehran University of Medical Sciences	Designed and conceptualized the study; integrated clinical and genomic findings; and revised the manuscript for important intellectual content
Michael C. Kruer, MD	Phoenix Children's Hospital	Designed and conceptualized the study; integrated clinical and genomic findings; and drafted and revised the manuscript

References

- van der Knaap MS, Smit LM, Barkhof F, et al. Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. Ann Neurol 2006;59(3):504-511.
- Labelle-Dumais C, Schuitema V, Hayashi G, et al. COL4A1 mutations cause neuromuscular disease with tissue-specific mechanistic heterogeneity. Am J Hum Genet 2019;104(5):847-860.
- Zagaglia S, Selch C, Nisevic JR, et al. Neurologic phenotypes associated with CO-L4A1/2 mutations: expanding the spectrum of disease. Neurology 2018;91(22): e2078-e2088.
- Yaramis A, Lochmüller H, Töpf A, et al. COL4A1-related autosomal recessive encephalopathy in 2 Turkish children. Neurol Genet 2020;6(1):e392.
- Jin SC, Lewis SA, Bakhtiari S, et al. Mutations disrupting neuritogenesis genes confer risk for cerebral palsy. Nat Genet 2020;52:1046-1056.
- Jeanne M, Gould DB. Genotype-phenotype correlations in pathology caused by collagen type IV alpha 1 and 2 mutations. *Matrix Biol* 2017;57-58:29-44.
- Fahey MC, Maclennan AH, Kretzschmar D, Gecz J, Kruer MC. The genetic basis of cerebral palsy. Dev Med Child Neurol 2017;59(5):462-469.



Recessive COL4A2 Mutation Leads to Intellectual Disability, Epilepsy, and Spastic Cerebral Palsy Somayeh Bakhtiari, Abbas Tafakhori, Sheng Chih Jin, et al. Neurol Genet 2021;7; DOI 10.1212/NXG.00000000000583

This information is current as of April 26, 2021

Neurol Genet is an official journal of the American Academy of Neurology. Published since April 2015, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2376-7839.



Updated Information & Services	including high resolution figures, can be found at: http://ng.neurology.org/content/7/3/e583.full.html
References	This article cites 7 articles, 1 of which you can access for free at: http://ng.neurology.org/content/7/3/e583.full.html##ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Cerebrovascular disease/Stroke http://ng.neurology.org//cgi/collection/all_cerebrovascular_disease_str oke All Epilepsy/Seizures http://ng.neurology.org//cgi/collection/all_epilepsy_seizures All Genetics http://ng.neurology.org//cgi/collection/all_genetics All Movement Disorders http://ng.neurology.org//cgi/collection/all_movement_disorders Developmental disorders http://ng.neurology.org//cgi/collection/developmental_disorders
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://ng.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://ng.neurology.org/misc/addir.xhtml#reprintsus

Neurol Genet is an official journal of the American Academy of Neurology. Published since April 2015, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2376-7839.

